Cardiac Biomarkers Market

Global Cardiac Biomarkers Market Size, Share & Trends Analysis Report
and Segment Forecast, 2024 | Grand View Research, Inc
“The high prevalence rates of cardiovascular diseases worldwide and the rise
in popularity in POC cardiac testing kits are expected to fuel the Cardiac
Biomarkers Market growth.”
The Cardiac Biomarkers Market is expected to reach USD13.3 billion by 2024, according to a new report by Grand
View Research, Inc. The cardiac biomarkers market is anticipated to witness a lucrative growth during the forecast
period from 2016 to 2024. Analysis of global market trends focuses on the increasing demand for cardiac
biomarkers owing to its increased adoption in cardiovascular disease diagnosis. Furthermore, this growth is
attributed to a majority of factors, such as the high prevalence of Acute Coronary Syndrome (ACS), continual
technological advancements in the development of cardiovascular biomarkers, increasing number of new product
launches by the key market players, rising demand for point of care cardiac testing kits, along with the high
specificity and sensitivity of these biomarkers in the detection of cardiovascular diseases, especially acute
myocardial infarction.
The cardiac biomarkers market has been classified by type into troponin, Creatine kinase-MB(CK-MB), B-type
Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP), myoglobin, and others.
Troponin is a heteromeric protein and comprises cardiac troponin T & I, which are abbreviated as cTnT & cTnI,
respectively. The troponin biomarkers segment is expected to grow lucratively in the forecast period at a significant
CAGR. The diagnostic efficiency and specificity related to cardiac biomarker testing renders it a universally gold
standard test to diagnose cardiovascular disorders worldwide. The market by application is segmented into acute
coronary syndrome, myocardial infarction, congestive heart failure, and others. ACS is expected to be the highest
grossing segment according to the study. ACS is responsible for huge medical costs globally and is responsible for
most hospital readmission cases. The increasing efforts to cut down worldwide ACS prevalence rates are expected
to drive the growth of the biomarkers market.
Follow Us:
The key countries included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa,
and the Middle East. North America accounted for the largest market in 2015, whereas the Asia Pacific region is
anticipated to be the fastest growing region during the forecast period.
Access Research Report of Cardiac Biomarkers Market
http://www.grandviewresearch.com/industry-analysis/cardiac-biomarker-market
Further key findings from the study suggest:

North America is estimated to dominate the global cardiac biomarkers market. The high prevalence of
coronary heart disease in western countries is one of the major factors contributing to the high demand for
cardiac biomarker diagnostics.

The Asia Pacific region is anticipated to be the fastest growing region in the study period owing to the large
population, especially in China and India. Apart from that, there exists a high prevalence rate of myocardial
infarction in the region. This prevalence rate is expected to fuel the demand for cardiac biomarker
diagnostics.

The troponin biomarker segment is expected to grow at a significant rate, and is expected to grow at the
highest CAGR compared to others and accounts for the largest market share in 2015.

The sector comprises of several local as well as global players. Some of the major players of this vertical
include Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher
Scientific, Inc., Becton, Dickinson and Company, and bioMerieux SA.
Grand View Research has segmented the cardiac biomarkers market on the basis of type, application, end use, and
region:
Cardiac Biomarkers Type Outlook (Revenue, USD Million, 2013 - 2024)

Troponin

CK-MB

Natriuretic peptides - BNP and NT-proBNP

Myoglobin

Others
Cardiac Biomarkers Market Application Outlook (Revenue, USD Million, 2013 - 2024)

Acute Coronary Syndrome

Myocardial infarction
Follow Us:

Congestive heart failure

Others
Cardiac Biomarkers Market End-use Outlook (Revenue, USD Million, 2013 - 2024)

Laboratory Testing

Point of Care Testing
Cardiac Biomarkers Regional Outlook (Revenue, USD Million, 2013 - 2024)





North America
o
U.S.
o
Canada
Europe
o
Germany
o
UK
Asia Pacific
o
China
o
India
Latin America
o
Brazil
o
Mexico
MEA
o
South Africa
o
Middle East
Related Report @ https://www.grandviewresearch.com/industry-analysis/biomarkers-industry
Follow Us:
Table of Content of Cardiac Biomarkers Market
Table of Content
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Snapshot
Chapter 4. Market Variables, Trends & Scope
4.1. Market segmentation & scope
4.2. Cardiac biomarkers: Market dynamics
4.2.1. Market driver analysis
4.2.2. Market restraint analysis
4.3. Penetration & growth prospect mapping
4.4. Cardiac Biomarkers - SWOT Analysis, By Factor (political & legal, economic and technological)
4.5. Industry Analysis - Porter’s
4.6. Cardiac Biomarkers Market: Company Market Share Analysis, 2015
Chapter 5. Market Categorization 1: Cardiac Biomarkers Type Estimates & Trend Analysis
5.1. Cardiac Biomarkers Market: Type Movement Analysis
5.2. Troponin
5.2.1. Market estimates and forecasts, 2013 - 2024 (USD Million)
5.3. CK-MB
5.3.1. Market estimates and forecasts, 2013 - 2024 (USD Million)
5.4. Natriuretic Peptides (BNP and NT-proBNP)
5.4.1. Market estimates and forecasts, 2013 - 2024 (USD Million)
5.5. Myoglobin
5.5.1. Market estimates and forecasts, 2013 - 2024 (USD Million)
5.6. Others
5.6.1. Market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 6. Market Categorization 2: Cardiac Biomarkers Application Estimates & Trend Analysis
6.1. Cardiac Biomarkers Market: Application Movement Analysis
6.2. Acute Myocardial Infarction (AMI)
Follow Us:
6.2.1. Market estimates and forecasts, 2013 - 2024 (USD Million)
6.3. Congestive Heart Failure (CHF)
6.3.1. Market estimates and forecasts, 2013 - 2024 (USD Million)
6.4. Acute Coronary Syndrome (ACS)
6.4.1. Market estimates and forecasts, 2013 - 2024 (USD Million)
6.5. Others
6.5.1. Market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 7. Market Categorization 3: Cardiac Biomarkers End-use Estimates & Trend Analysis
7.1. Cardiac Biomarkers Market: End-use Movement Analysis
7.2. Laboratory Testing
7.2.1. Market estimates and forecasts, 2013 - 2024 (USD Million)
7.3. Point of Care Testing
7.3.1. Market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 8. Cardiac biomarkers: Regional Estimates & Trend Analysis, by Type, Application, & End-use
8.1. Cardiac biomarkers Market Share (%) Analysis, by Region, 2016 & 2024
8.2. North America
8.2.1. U.S.
8.2.1.1. U.S. Cardiac biomarkers market, by type, 2013 - 2024 (USD Million)
8.2.1.2. U.S. Cardiac biomarkers market, by application, 2013 - 2024 (USD Million)
8.2.1.3. U.S. Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million)
8.2.2. Canada
8.2.2.1. Canada Cardiac biomarkers market, by type, 2013 - 2024 (USD Million)
8.2.2.2. Canada Cardiac biomarkers market, by application, 2013 - 2024 (USD Million)
8.2.2.3. Canada Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million)
8.3. Europe
8.3.1. Germany
8.3.1.1. Germany Cardiac biomarkers market, by type, 2013 - 2024 (USD Million)
8.3.1.2. Germany Cardiac biomarkers market, by application, 2013 - 2024 (USD Million)
8.3.1.3. Germany Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million)
8.3.2. UK
8.3.2.1. UK Cardiac biomarkers market, by type, 2013 - 2024 (USD Million)
Follow Us:
8.3.2.2. UK Cardiac biomarkers market, by application, 2013 - 2024 (USD Million)
8.3.2.3. UK Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million)
8.4. Asia Pacific
8.4.1. China
8.4.1.1. China Cardiac biomarkers market, by type, 2013 - 2024 (USD Million)
8.4.1.2. China Cardiac biomarkers market, by application, 2013 - 2024 (USD Million)
8.4.1.3. China Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million)
8.4.2. India
8.4.2.1. India Cardiac biomarkers market, by type, 2013 - 2024 (USD Million)
8.4.2.2. India Cardiac biomarkers market, by application, 2013 - 2024 (USD Million)
8.4.2.3. India Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million)
8.5. Latin America
8.5.1. Brazil
8.5.1.1. Brazil cardiac biomarkers market, by type, 2013 - 2024 (USD Million)
8.5.1.2. Brazil cardiac biomarkers market, by application, 2013 - 2024 (USD Million)
8.5.1.3. Brazil cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million)
8.5.2. Mexico
8.5.2.1. Mexico cardiac biomarkers market, by type, 2013 - 2024 (USD Million)
8.5.2.2. Mexico cardiac biomarkers market, by application, 2013 - 2024 (USD Million)
8.5.2.3. Mexico cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million)
8.6. Middle East Africa
8.6.1. South Africa
8.6.1.1. South Africa cardiac biomarkers market, by type, 2013 - 2024 (USD Million)
8.6.1.2. South Africa cardiac biomarkers market, by application, 2013 - 2024 (USD Million)
8.6.1.3. South Africa cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million)
8.6.2. Middle East
8.6.2.1. Middle East cardiac biomarkers market, by type, 2013 - 2024 (USD Million)
8.6.2.2. Middle East cardiac biomarkers market, by application, 2013 - 2024 (USD Million)
8.6.2.3. Middle East cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Profiles
Follow Us:
9.1.1. Abbott Laboratories
9.1.1.1. Company Overview
9.1.1.2. Financial Performance
9.1.1.3. Product Benchmarking
9.1.1.4. Strategic Initiatives
9.1.2. Alere, Inc.
9.1.2.1. Company Overview
9.1.2.2. Financial Performance
9.1.2.3. Product Benchmarking
9.1.2.4. Strategic Initiatives
9.1.3. Siemens Healthcare GmbH
9.1.3.1. Company Overview
9.1.3.2. Financial Performance
9.1.3.3. Product Benchmarking
9.1.3.4. Strategic Initiatives
9.1.4. Roche Diagnostics Corporation
9.1.4.1. Company Overview
9.1.4.2. Financial Performance
9.1.4.3. Product Benchmarking
9.1.4.4. Strategic Initiatives
9.1.5. Beckman Coulter, Inc.
9.1.5.1. Company Overview
9.1.5.2. Financial Performance
9.1.5.3. Product Benchmarking
9.1.5.4. Strategic Initiatives
9.1.6. Becton, Dickinson &Co.
9.1.6.1. Company Overview
9.1.6.2. Financial Performance
9.1.6.3. Product Benchmarking
9.1.6.4. Strategic Initiatives
9.1.7. Thermo Fisher Scientific, Inc.
Follow Us:
9.1.7.1. Company Overview
9.1.7.2. Financial Performance
9.1.7.3. Product Benchmarking
9.1.7.4. Strategic Initiatives
9.1.8. bioMérieux SA
9.1.8.1. Company Overview
9.1.8.2. Financial Performance
9.1.8.3. Product Benchmarking
9.1.8.4. Strategic Initiatives
9.1.9. Bio-Rad Laboratories, Inc.
9.1.9.1. Company Overview
9.1.9.2. Financial Performance
9.1.9.3. Product Benchmarking
9.1.9.4. Strategic Initiatives
9.1.10. BG Medicines
9.1.10.1. Company Overview
9.1.10.2. Financial Performance
9.1.10.3. Product Benchmarking
9.1.10.4. Strategic Initiatives
Follow Us:
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed business decisions, the company offers
market intelligence studies ensuring relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: [email protected]
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Follow Us:

The high prevalence rates of cardiovascular diseases worldwide and the rise in popularity in POC cardiac testing kits are expected to fuel the market growth

Download Report